Zika virus has oncolytic activity against glioblastoma stem cells

Zhe Zhu, Matthew J. Gorman, Lisa D. McKenzie, Jiani N. Chai, Christopher G. Hubert, Briana C. Prager, Estefania Fernandez, Justin M. Richner, Rong Zhang, Chao Shan, Eric Tycksen, Xiuxing Wang, Pei-Yong Shi, Michael S. Diamond, Jeremy N. Rich, Milan G. Chheda

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity. We explored the use of oncolytic virus therapy against glioblastoma with Zika virus (ZIKV), a flavivirus that induces cell death and differentiation of neural precursor cells in the developing fetus. ZIKV preferentially infected and killed glioblastoma stem cells (GSCs) relative to differentiated tumor progeny or normal neuronal cells. The effects against GSCs were not a general property of neurotropic flaviviruses, as West Nile virus indiscriminately killed both tumor and normal neural cells. ZIKV potently depleted patient-derived GSCs grown in culture and in organoids. Moreover, mice with glioblastoma survived substantially longer and at greater rates when the tumor was inoculated with a mouse-adapted strain of ZIKV. Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thus, genetically modified strains that further optimize safety could have therapeutic efficacy for adult glioblastoma patients.

Original languageEnglish (US)
Pages (from-to)2843-2857
Number of pages15
JournalJournal of Experimental Medicine
Volume214
Issue number10
DOIs
StatePublished - 2017

Fingerprint

Glioblastoma
Stem Cells
Flavivirus
Oncolytic Virotherapy
Organoids
Oncolytic Viruses
West Nile virus
Neoplasms
Zika Virus
Brain Neoplasms
Cell Differentiation
Fetus
Cell Death
Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Zhu, Z., Gorman, M. J., McKenzie, L. D., Chai, J. N., Hubert, C. G., Prager, B. C., ... Chheda, M. G. (2017). Zika virus has oncolytic activity against glioblastoma stem cells. Journal of Experimental Medicine, 214(10), 2843-2857. https://doi.org/10.1084/jem.20171093

Zika virus has oncolytic activity against glioblastoma stem cells. / Zhu, Zhe; Gorman, Matthew J.; McKenzie, Lisa D.; Chai, Jiani N.; Hubert, Christopher G.; Prager, Briana C.; Fernandez, Estefania; Richner, Justin M.; Zhang, Rong; Shan, Chao; Tycksen, Eric; Wang, Xiuxing; Shi, Pei-Yong; Diamond, Michael S.; Rich, Jeremy N.; Chheda, Milan G.

In: Journal of Experimental Medicine, Vol. 214, No. 10, 2017, p. 2843-2857.

Research output: Contribution to journalArticle

Zhu, Z, Gorman, MJ, McKenzie, LD, Chai, JN, Hubert, CG, Prager, BC, Fernandez, E, Richner, JM, Zhang, R, Shan, C, Tycksen, E, Wang, X, Shi, P-Y, Diamond, MS, Rich, JN & Chheda, MG 2017, 'Zika virus has oncolytic activity against glioblastoma stem cells', Journal of Experimental Medicine, vol. 214, no. 10, pp. 2843-2857. https://doi.org/10.1084/jem.20171093
Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC et al. Zika virus has oncolytic activity against glioblastoma stem cells. Journal of Experimental Medicine. 2017;214(10):2843-2857. https://doi.org/10.1084/jem.20171093
Zhu, Zhe ; Gorman, Matthew J. ; McKenzie, Lisa D. ; Chai, Jiani N. ; Hubert, Christopher G. ; Prager, Briana C. ; Fernandez, Estefania ; Richner, Justin M. ; Zhang, Rong ; Shan, Chao ; Tycksen, Eric ; Wang, Xiuxing ; Shi, Pei-Yong ; Diamond, Michael S. ; Rich, Jeremy N. ; Chheda, Milan G. / Zika virus has oncolytic activity against glioblastoma stem cells. In: Journal of Experimental Medicine. 2017 ; Vol. 214, No. 10. pp. 2843-2857.
@article{08c58ed7a705424e84a11922f70e2933,
title = "Zika virus has oncolytic activity against glioblastoma stem cells",
abstract = "Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity. We explored the use of oncolytic virus therapy against glioblastoma with Zika virus (ZIKV), a flavivirus that induces cell death and differentiation of neural precursor cells in the developing fetus. ZIKV preferentially infected and killed glioblastoma stem cells (GSCs) relative to differentiated tumor progeny or normal neuronal cells. The effects against GSCs were not a general property of neurotropic flaviviruses, as West Nile virus indiscriminately killed both tumor and normal neural cells. ZIKV potently depleted patient-derived GSCs grown in culture and in organoids. Moreover, mice with glioblastoma survived substantially longer and at greater rates when the tumor was inoculated with a mouse-adapted strain of ZIKV. Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thus, genetically modified strains that further optimize safety could have therapeutic efficacy for adult glioblastoma patients.",
author = "Zhe Zhu and Gorman, {Matthew J.} and McKenzie, {Lisa D.} and Chai, {Jiani N.} and Hubert, {Christopher G.} and Prager, {Briana C.} and Estefania Fernandez and Richner, {Justin M.} and Rong Zhang and Chao Shan and Eric Tycksen and Xiuxing Wang and Pei-Yong Shi and Diamond, {Michael S.} and Rich, {Jeremy N.} and Chheda, {Milan G.}",
year = "2017",
doi = "10.1084/jem.20171093",
language = "English (US)",
volume = "214",
pages = "2843--2857",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "10",

}

TY - JOUR

T1 - Zika virus has oncolytic activity against glioblastoma stem cells

AU - Zhu, Zhe

AU - Gorman, Matthew J.

AU - McKenzie, Lisa D.

AU - Chai, Jiani N.

AU - Hubert, Christopher G.

AU - Prager, Briana C.

AU - Fernandez, Estefania

AU - Richner, Justin M.

AU - Zhang, Rong

AU - Shan, Chao

AU - Tycksen, Eric

AU - Wang, Xiuxing

AU - Shi, Pei-Yong

AU - Diamond, Michael S.

AU - Rich, Jeremy N.

AU - Chheda, Milan G.

PY - 2017

Y1 - 2017

N2 - Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity. We explored the use of oncolytic virus therapy against glioblastoma with Zika virus (ZIKV), a flavivirus that induces cell death and differentiation of neural precursor cells in the developing fetus. ZIKV preferentially infected and killed glioblastoma stem cells (GSCs) relative to differentiated tumor progeny or normal neuronal cells. The effects against GSCs were not a general property of neurotropic flaviviruses, as West Nile virus indiscriminately killed both tumor and normal neural cells. ZIKV potently depleted patient-derived GSCs grown in culture and in organoids. Moreover, mice with glioblastoma survived substantially longer and at greater rates when the tumor was inoculated with a mouse-adapted strain of ZIKV. Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thus, genetically modified strains that further optimize safety could have therapeutic efficacy for adult glioblastoma patients.

AB - Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity. We explored the use of oncolytic virus therapy against glioblastoma with Zika virus (ZIKV), a flavivirus that induces cell death and differentiation of neural precursor cells in the developing fetus. ZIKV preferentially infected and killed glioblastoma stem cells (GSCs) relative to differentiated tumor progeny or normal neuronal cells. The effects against GSCs were not a general property of neurotropic flaviviruses, as West Nile virus indiscriminately killed both tumor and normal neural cells. ZIKV potently depleted patient-derived GSCs grown in culture and in organoids. Moreover, mice with glioblastoma survived substantially longer and at greater rates when the tumor was inoculated with a mouse-adapted strain of ZIKV. Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thus, genetically modified strains that further optimize safety could have therapeutic efficacy for adult glioblastoma patients.

UR - http://www.scopus.com/inward/record.url?scp=85030245284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030245284&partnerID=8YFLogxK

U2 - 10.1084/jem.20171093

DO - 10.1084/jem.20171093

M3 - Article

C2 - 28874392

AN - SCOPUS:85030245284

VL - 214

SP - 2843

EP - 2857

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 10

ER -